A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Public ClinicalTrials.gov record NCT02576717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
Study identification
- NCT ID
- NCT02576717
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,494 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2015
- Primary completion
- Jan 4, 2023
- Completion
- Jan 4, 2023
- Last update posted
- Jan 29, 2024
2015 – 2023
United States locations
- U.S. sites
- 19
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 115 | Phoenix | Arizona | 85004 | — |
| Local Institution - 118 | Phoenix | Arizona | 85013 | — |
| Local Institution - 110 | Berkeley | California | 94705 | — |
| Local Institution - 103 | Fresno | California | 93710 | — |
| Local Institution - 122 | Long Beach | California | 90806 | — |
| Local Institution - 112 | Sacramento | California | 95817 | — |
| Local Institution - 120 | San Francisco | California | 94158 | — |
| Local Institution - 114 | Maitland | Florida | 32751 | — |
| Local Institution - 123 | Port Charlotte | Florida | 33952 | — |
| Local Institution - 124 | Sunrise | Florida | 33351 | — |
| Local Institution - 147 | Tampa | Florida | 33609 | — |
| Local Institution - 137 | Golden Valley | Minnesota | 55422 | — |
| Local Institution - 170 | Las Vegas | Nevada | 89106 | — |
| Local Institution - 143 | Raleigh | North Carolina | 27607 | — |
| Local Institution - 107 | Westerville | Ohio | 43801 | — |
| Local Institution - 144 | Knoxville | Tennessee | 37922 | — |
| Local Institution - 138 | Lubbock | Texas | 79410 | — |
| Local Institution - 179 | Round Rock | Texas | 78681 | — |
| Local Institution - 141 | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 156 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02576717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02576717 live on ClinicalTrials.gov.